3D layered co-culture model enhances Trastuzumab Deruxtecan …
WEBJun 11, 2024 · Trastuzumab deruxtecan (T-DXd), a HER2-targeted antibody-drug conjugate has been approved as the first HER2-targeted drug for HER2-mutant lung cancer. However, some cases are not responsive to T-DXd and the primary resistant mechanism remains unclear.
3D layered co-culture model enhances Trastuzumab Deruxtecan …
WEBTrastuzumab deruxtecan (T-DXd), an anti-HER2 antibody drug conjugate (ADC), was developed and recently approved for the treatment of several types of HER2-positive cancer. T-DXd is composed of trastuzumab and the topoisomerase-I (TOP1) inhibitor DXd, linked by an enzymatically cleavable linker [9]. T-DXd has been used for the treatment of …
3D layered co-culture model enhances Trastuzumab Deruxtecan …
WEB3D layered co-culture of HER2-mutant NSCLC cells formed a lumen-like structure. • 3D co-culture model is useful to evaluate the efficacy of T-DXd, an anti-HER2-ADC. • G007-LK, a tankyrase inhibitor, sensitized HER2-positive NSCLC cells to T-DXd.
Trastuzumab deruxtecan in HER2-positive breast cancer with …
WEBAug 8, 2022 · Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We conducted the...
Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for
WEBOct 7, 2021 · Trastuzumab deruxtecan (T-DXd) is a novel antibody–drug conjugate with a tetrapeptide linker, which delivers a topoisomerase I inhibitor with a drug-to-antibody ratio of 7~8. The potency of the active payload, as well as its significant bystander effect, resulted in significant anti-tumor activity.
Trastuzumab Deruxtecan in Previously Treated HER2-Low …
WEBJun 5, 2022 · Trastuzumab deruxtecan (formerly DS-8201), an antibody–drug conjugate consisting of a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor payload through a...
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for …
WEBMar 23, 2022 · We conducted a phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of trastuzumab deruxtecan (a HER2 antibody–drug conjugate) with those of trastuzumab ...
Abstract 1141: Pharmacokinetic and pharmacodynamic evaluation …
WEBJun 15, 2022 · Introduction: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate comprised of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor approved for the treatment of HER2 positive metastatic breast and gastric cancer.
3D layered co-culture model enhances Trastuzumab Deruxtecan …
WEBJun 1, 2024 · 3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer.
Treatment with trastuzumab deruxtecan in patients with HER2 …
WEBOct 11, 2023 · Here, we report on the effectiveness and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2-positive breast cancer patients with BM.
Skip to content